Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPT113
- Development stage
- Unknown
- Lead developer
- Hangzhou DAC Biotech
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CPT113 is a proprietary Topoisomerase I (TOPO1) inhibitor payload and linker-payload technology developed for use in antibody-drug conjugates (ADCs). It serves as the cytotoxic warhead that, upon release within target cancer cells, inhibits DNA Topoisomerase I, leading to lethal DNA strand breaks and apoptosis. CPT113 is a key component of the CrossConju™ conjugation platform, which is designed to enable high drug-to-antibody ratios (DAR) and enhanced stability. It is incorporated into several ADC candidates, including DXC1002 (targeting TROP2) and DXC006 (targeting CD56), as well as programs targeting PTK7, SEZ6, and MUC16. The technology was developed by researchers at Duality Biologics.
- Other names
- CPT113-cleavable linker-payloadCPT-113-cleavable linker-payloadCPT 113-cleavable linker-payloadCPT113 payloadCPT-113 payloadCPT 113 payload
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on CPT113.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPT113.